Due to the good predictive effect of risk scores in the liver cancer immunotherapy queue treated with anti-PD1/PDL1, SIR-PS may affect the efficacy of immunotherapy by affecting PDL1 expression. The gene discussed is CD274; the disease is liver cancer.